This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Xeris Pharmaceuticals (XERS) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Do Options Traders Know Something About Xeris Pharmaceuticals (XERS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
Xeris Pharmaceuticals (XERS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 35.19% and 111.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.
Xeris Pharmaceuticals (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Xeris Pharmaceuticals (XERS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
Xeris Pharmaceuticals (XERS) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares more than 5% on the day, amid huge volumes.
Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 11.27% and -11.18%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals (XERS) in Focus: Stock Moves 6.8% Higher
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Company News for May 26, 2020
by Zacks Equity Research
Companies In The News Are: TTWO, XERS, SPLK, NAVB
Xeris Pharmaceuticals Inc (XERS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals Inc (XERS) delivered earnings and revenue surprises of 3.26% and -7.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Xeris' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Xeris Pharmaceuticals.
Eiger Completes NDA Submission of Progeria Drug Lonafarnib
by Zacks Equity Research
Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.
Xeris Pharmaceuticals, Inc. (XERS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 0.81% and 144.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Xeris Pharmaceuticals, Inc. (XERS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals, Inc. (XERS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 3.17% and 61.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Xeris Pharmaceuticals, Inc. (XERS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of -31.96% and 57.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.